TOTAL: $493.22M

Company
(Symbol)#

Type Of
Financing

Number Of
Shares, Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details (Date)@ ($M)

Alliance Pharmaceutical Corp. (ALLP)

Debenture financing

­

$10

Alliance received $10M from the sale of subordinated convertible debentures to a small group of investors, who have the option to purchase an additional $10M of debentures convertible into stock at $16 per share for four years after issuance (8/22)

Antisoma plc (UK; LSE:ASM)

Private Placement

7.68S

#8.7 (US$13)

Antisoma raised #8.7M (US$13) by placing 7.68M shares at #1.17 per share, a discount of 8 percent to the July 26 closing price (7/27)

Aviron (AVIR)

Private placement

0.262S

$8

Aviron sold 262,200 shares to Acqua Wellington Asset Management LLC for an aggregate price of $8M, or $30.51 per share; the company did not pay any fees in connection with the transaction (8/8)

Bioject Medical Technologies Inc. (BJCT)

Equity financing

1.4S

$10.5

Bioject completed the final segment of a private equity financing with the sale of 150,000 shares at $7.88 per share, bringing the total financing to $10.5M net, represent- ing about 1.4M shares; Lone Pine Capital acted as the lead investor and five other investors participated (8/4)

Caliper Technologies Corp. (CALP)

Private placement of common stock

2.3S

$110.4

Caliper sold 2.3M shares at $48 per share, representing a discount to market price (8/30)

Cerus Corp. (CERS)

Private placement

1.2S

$60

Cerus raised $60M through the issuance of 1.2M shares at $50 per share (8/29)

CombiMatrix Corp., majority- owned affiliate of Acacia Research Corp. (ACRI)

Private equity financing

­

$36

Investors included Acacia Research, Emerging Growth Management, JDS Capital, Oracle Partners, OrbiMed Advisors, SAC Capital Management, Seneca Capital and Wheatley Partners (8/3)

Coulter Pharmaceutical Inc. (CLTR)

Private placement

1.655S

$35.8

Coulter entered into an agreement to sell 1.655M shares at $21.625 per share, raising $35.8M; Pacific Growth Equities Inc. served as the placement agent (8/14)

CV Therapeutics Inc. (CVTX)

Common stock equity

­

­

CV received a commitment for up to $120M in common stock equity financing from Acqua Wellington North American Equities Fund Ltd.; CV may sell shares at its discretion and at a small discount to the market price over the next 28 months (8/8)

Derma Sciences Inc. (DSCIC)

Private financing

0.67U

$0.5

Derma concluded an agreement with three investment firms to sell $500,000 of the company's Series E units at $0.75 per unit; the units consist of one share and 1.1 warrant to purchase one share at $0.85 per share; the warrants expire July 18, 2005; purchasers included Kensington Capital Management LLC, Dolphin Offshore Partners and Redwood Asset Management (8/23)

Genelabs Technologies Inc. (GNLB)

Equity financing

0.78S

$3.11

Genelabs sold 779,271 shares to Acqua Wellington North American Equities Fund Ltd. for $3.99 per share; the company did not pay any fees in connection with the transaction (8/9)

Immunex Corp. (IMNX)

Shelf registration

70S

­

Immunex filed for a shelf registration to sell up to 70M shares, 20M from the comp- any and 50M from American Home Products Corp., which holds 283.9M shares; terms will be determined at the time of the offering (8/9)

Incara Pharmaceuticals Corp. (INCR)

Equity financing facility

­

­

Incara entered into a definitive agreement with Torneaux Fund Ltd. to sell stock over 15 months; the amount of the investment is dependent on Incara's stock price and is ex- pected to exceed $3M, but is capped at $18.9M (8/18)

Interferon Sciences Inc. (OTCBB:IFSC)

Private placement of units

11.64U

$7.7

Interferon raised $7.7M from the sale of 11.64 units, which each contain one share of common stock and a warrant, exercisable until April 2005, to purchase one share at $1.50 (8/8)

InterMune Pharmaceuticals Inc. (ITMN)

Private placement of stock

2S

$76

InterMune raised $76M through a private placement of 2M shares at $38 per share; Prudential Vector Healthcare Group was the lead placement agent; co-placement agents were Lehman Brothers and UBS Warburg LLC (8/17)

Magainin Pharmaceuticals Inc. (MAGN)

Private placement

4.1S

$12.4

Magainin sold 4.1M shares at $3 per share, raising $12.4M; both existing and new in- vestors participated, including the State of Wisconsin Investment Board; Paramount Capital Inc. was financial adviser (8/11)

Matritech Inc. (NMPS)

Equity financing

2.45S

­

Matritech entered into an agreement with Acqua Wellington North American Equities Fund Ltd. to sell over 14 months up to 2.45M shares that are part of a shelf registration; the shares may be sold at a small discount to market and the total investment is dependent on the company's stock price (8/24)

Myriad Genetics Inc. (MYGN)

Equity placement

0.175S

$22

Myriad received $22M in a direct equity placement with Acqua Wellington North American Equities Fund Ltd.; the 175,000 shares were sold at a small discount to the market price (8/29)

NeoRx Corp. (NERX)

Private placement

2.45S

$37

NeoRx sold 2.45M shares to institutional investors led by Lone Pine Capital LLC, Capital Research and Management Co., and Deerfield Management, raising $36M in net proceeds; following the offering, the company has 26M shares outstanding; Adams, Harkness & Hill Inc. acted as placement agent(8/29)

NexMed Inc.(NEXM)

Private equity placement

2.008S

$16.68

NexMed sold 2.008M shares, raising $16.68M; investors paying $18 per unit received two shares at $9 per share and one warrant to purchase one share at $13.50; investors paying $16.54 per unit received two shares at $8.27 per share and one warrant to purchase 0.7 share at $13.50; all warrants may be exercised over the next 18 months; investors included Capital Research and Management Co. and a mutual fund managed by a major investment firm; AmeriCal Securities Inc. acted as the placement agent (8/2)

NexMed Inc. (NEXM)

Private equity placement

1.13S

$10.17

NexMed sold an additional 1.13M shares, raising an additional $10.17M; investors paid $18 per unit and received two shares at $9 per share and one 18-month warrant to purchase one share at $16.20 per share; AmeriCal Securities Inc. and Shannon Limited acted as placement agents (8/9)

Oxford Biomedica plc (UK; LSE:OXB)

Private placement of ordinary shares

14.6S

#8.5 (US$12.8)

Oxford raised #8.5M through the issuance of 14.6M ordinary shares at 60 pence per share (8/10)

Paracelsian Inc. (OTC:PRLN)

Private equity investment

­

$0.5

Paracelsian received an equity investment of $0.5M and also issued warrants that could result in an additional investment of $1.5M by Dec. 31 if the warrants are exercised in full (8/10)

StemCells Inc. (STEM)

Private placement

0.924S

$4

StemCells completed a $4M common stock financing, receiving $3M at closing and will receive $1M more upon effectiveness of a reg- istration statement covering shares owned by the investment fund; the fund purchased the stock at $4.33 per share and will be entitled to receive additional shares on eight dates; the fund also has the option for 12 months to purchase up to $3M of additional common stock (8/7)

Syn X Pharma Inc. (CDNX:SYY

Private placement of special warrants

­

C$5.8 (US$3.9M)

Each warrant will be exercisable into one common share and one common share purchase warrant, which has a term of two years and entitles the holder to purchase one common share at C$4 in the first year and C$4.25 in the second year; 50 percent of proceeds go to Syn X and 50 percent will go in escrow pending the comp-any's achievement of two of six milestones; Octagon Capital Corp. and Thomson Kernaghan & Co. Ltd. led the placement (8/16)

Vion Pharmaceuticals Inc. (VION)

Exercise of purchase options

0.113U

$2.76

Holders of Vion's remaining 113,333 unit purchase options exercised them, giving the company $2.76M and resulting in the issuance of 494,816 shares; Vion now has 25.96M shares outstanding (8/14)

Notes:
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
* Non-U.S. currencies converted at the exchange rate on the date of the announcement.
@ Dates refer to the date of the press release.
ASX = Australian Stock Exchange
LSE = London Stock Exchange
TSE = Toronto Stock Exchange
VSE = Vancouver Stock Exchange
OTC BB = Over The Counter Bulletin Board

No Comments